Alvotech
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ALVO in the last 7 days.
No SEC Form 4 filings for $ALVO in the last 30 days.
See all $ALVO insider activity →Alvotech announced that the US FDA has accepted its Biologics License Application for AVT80, a proposed biosimilar to Entyvio. This development could impact Alvotech's market position and investor sentiment.
Alvotech (ALVO) rose 11.7% after announcing a licensing deal with Lotus Pharmaceutical for biosimilars AVT34 and AVT87, with up to $150M in payments. The company updated 2026 revenue guidance to $650–700M and reported a half-year net loss of $65.79M. Analysts note the deal expands market access but regulatory approvals remain key.
Alvotech (ALVO) shares rose 18.51% to $5.25 after Bank of America initiated a 'buy' rating with a $7 price target. The FDA voluntarily closed its inspection of Alvotech's Iceland facility. Alvotech also announced a commercialization agreement with Lotus Pharmaceutical for two drug candidates, AVT34 and AVT87. BofA's EPS projections differ from consensus estimates.
Recent ALVO coverage spans market movers, financial news and regulation.
Positive regulatory step could boost Alvotech's valuation and attract speculative buying.
Positive catalyst from the Lotus deal and higher guidance should support further upside.
Positive analyst upgrade and regulatory clearance likely support further price gains.
Buy initiation may attract biotech investors.
Analyst upgrade and price objective suggest upside potential.
AlphAI scores every news story that mentions ALVO with an AI model for sentiment and relevance, and aggregates insider trades from Alvotech's SEC EDGAR Form 4 filings. Figures refresh continuously.
Alvotech announced that the US FDA has accepted its Biologics License Application for AVT80, a proposed biosimilar to Entyvio. This development could impact Alvotech's market position and investor sentiment.
1 min readAlvotech (ALVO) rose 11.7% after announcing a licensing deal with Lotus Pharmaceutical for biosimilars AVT34 and AVT87, with up to $150M in payments. The company updated 2026 revenue guidance to $650–700M and reported a half-year net loss of $65.79M. Analysts note the deal expands market access but regulatory approvals remain key.
2 min readAlvotech (ALVO) shares rose 18.51% to $5.25 after Bank of America initiated a 'buy' rating with a $7 price target. The FDA voluntarily closed its inspection of Alvotech's Iceland facility. Alvotech also announced a commercialization agreement with Lotus Pharmaceutical for two drug candidates, AVT34 and AVT87. BofA's EPS projections differ from consensus estimates.
2 min readAnalysts made several ratings changes: UBS upgraded Celestica to Buy with a $430 target, citing AI-driven demand. Citi initiated Reformation as Buy with a $20 target. Morgan Stanley initiated Jersey Mike's and ArcelorMittal as Overweight. Baird upgraded Darden to Outperform and downgraded Chipotle to Neutral. Other notable moves include upgrades for Suzano, Ionic Digital, and Fortune Brands, while Canada Goose was downgraded.
2 min readBofA initiated coverage of Alvotech with a 'buy' rating and $7 price target, citing FDA approval and upcoming biosimilar launches. The stock rose 2.7% in pre-market trading. BofA forecasts 2026 EPS of $0.01, below consensus, and expects profitability growth through 2028. Key risks include regulatory delays and IP disputes.
2 min readAlvotech (NASDAQ: ALVO) and Lotus Pharmaceutical (TWSE: 1795) agreed to license and commercialize two biosimilars, AVT34 (durvalumab) and AVT87 (emicizumab), in the U.S. and Asia. The deal could bring Alvotech up to $150M in upfront and milestone payments. Alvotech retains U.S. commercialization rights while Lotus handles Asian markets.
2 min readAlvotech (ALVO) furnished an SEC Form 6-K — earnings release. Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of
2 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min readAlvotech said the U.S. FDA closed its May 2026 inspection of its Reykjavik, Iceland manufacturing site and classified it as Voluntary Action Indicated (VAI). The company said it is continuing to work with the FDA on biologics license applications for AVT05 (Simponi) and AVT06 (Eylea), and that the FDA accepted AVT16 (Entyvio). ALVO stock was $3.53, up 13.87%.
3 min readAlvotech (NASDAQ: ALVO) said it amended its credit agreement to add a $75 million term loan facility maturing Dec. 31, 2027, led by GoldenTree Asset Management. The financing follows a $165 million equity raise on June 18, 2026, bringing total new capital access to $240 million (equity plus undrawn loan). Funds support R&D and global product launches.
4 min read
